|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
ALP56 may contribute to colorectal adenoma formation and to an exophytic growth pattern in these adenomas.
|
12802606 |
2004 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
ALP56 may contribute to colorectal adenoma formation and to an exophytic growth pattern in these adenomas.
|
12802606 |
2004 |
|
AICARDI-GOUTIERES SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Both strains are genetically identical to the AGS susceptible DBA/2 (D2) strain except for a small amount of C57BL/6N (B6N) genome surrounding the Ahr locus and encompassing the Asp1 locus.
|
10656108 |
1998 |
|
Alzheimer Disease, Early Onset
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This activity appears highly increased by the presence (N-terminally to Asp-1) of a double-mutation (KM-->NL) found in several Swedish families affected by early onset Alzheimer's disease.
|
9098524 |
1997 |
|
Alzheimer Disease, Late Onset
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that genetic variation at the BACE2 locus modifies AD risk for those individuals who don't carry the ε4 variant of APOE.
|
31270419 |
2019 |
|
Alzheimer Disease, Late Onset
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We have tested, in a two-stage association study, whether allelic or haplotype variation of the beta-amyloid cleaving enzyme-2 (BACE2) locus on chromosome 21q affects the risk of late-onset AD.
|
16023140 |
2005 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the involvement of BACE2 in AD pathogenesis, we compared BACE2 and BACE1 gene regulation and their functions in Abeta generation.
|
15857888 |
2005 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.
|
29613789 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since BACE2 is located on chromosome 21, it is speculated that BACE2 may play a role in AD pathogenesis in DS.
|
16816112 |
2006 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Particularly, a subtle structural difference around the DTG/DSG active site between the two structures has been observed that is useful for the in-depth selectivity study of BACE1 and BACE2 inhibitors, stimulating new therapeutic strategies for the treatment of Alzheimer's disease and Down syndrome as well.
|
15473697 |
2005 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
|
17511655 |
2007 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
APP and BACE2 are 2 genes located in chromosome 21 and related to AD.
|
24462566 |
2014 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE2 (β-site APP-cleaving enzyme 2) is a protease localized in the brain, where it appears to play a role in the development of Alzheimer disease (AD).
|
25342134 |
2015 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that sequence variation in the BACE1 or BACE 2 gene is not a significant risk factor for AD; however, a combination of a specific BACE1 allele and APOE epsilon 4 may increase the risk for Alzheimer disease over and above that attributed to APOE epsilon 4 alone.
|
12707937 |
2003 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer's Disease and CSF Amyloid Biomarkers in APOE ε4 Non-Carriers.
|
31270419 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, our system links the expression of the Alzheimer's disease hallmark gene APP (amyloid-beta precursor protein) to the beta-site-cleaving enzymes BACE and BACE2, the gamma-site-cleaving enzymes presenilin 1 and 2, apolipoprotein E, and other Alzheimer's disease-related genes.
|
15492223 |
2004 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of Zn2+ binding on the structural and dynamic properties of amyloid β peptide associated with Alzheimer's disease: Asp1 or Glu11?
|
23947440 |
2013 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The β-amyloid cleaving enzymes 1 and 2 (BACE1 and BACE2) have been regarded as the prospective targets for clinically treating Alzheimer's disease (AD) in the last two decades.
|
31545898 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study.
|
16023140 |
2005 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease.
|
19124009 |
2009 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elucidation of the mechanism underlying BACE2 degradation is important for defining its biological features and its potential role in Alzheimer's disease drug development.
|
23773066 |
2013 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE2 could be involved in the Alzheimer-like neuropathology of Down syndrome, as well as in Alzheimer's disease linked to chromosome 21 but not showing mutations in APP.
|
10965118 |
2000 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study.
|
16023140 |
2005 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BACE2 activity did not change significantly in the AD brain, and was not related to Abeta concentration.
|
19968762 |
2010 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, BACE2 contributes to AD pathogenesis as a conditional β-secretase and could be a preventive and therapeutic target for AD without the side effects of BACE1 inhibition.
|
30626751 |
2019 |